Kilimanjaro IPTi Drug Options Trial

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

2,419

Participants

Timeline

Start Date

January 31, 2005

Primary Completion Date

April 30, 2008

Study Completion Date

June 30, 2008

Conditions
Malaria
Interventions
DRUG

sulphadoxine-pyrimethamine

DRUG

mefloquine

DRUG

Chlorproguanil-dapsone

DRUG

Placebo

Placebo

DRUG

Sulphadoxine-pryrimethamine

IPTi doses 1 and 2, at ages 2 and 3 months, sulphadoxine 250mg, pyrimethamine 12.5mg IPTi doses 3, at 9 months of age, sulphadoxine 500mg, pyrimethamine 25mg

DRUG

IPTi mefloquine

IPTi doses 1 \& 2 at ages 2 \& 3 months, mefloquine 125mg IPTi dose 3 at 9 months, mefloquine 250mg

DRUG

Chlorproguanil dapsone

IPTi doses 1 and 2 at ages 2 and 3 months, doses 15mg chlorproguanil and 18.75mg dapsone IPTi dose 3 at 9 months of age, doses 22.5mg chlorproguanil and 28.13mg dapsone

Trial Locations (1)

Unknown

Ministry of Health, Korogwe and Same District MCH clinics, Tanga

All Listed Sponsors
collaborator

University of Copenhagen

OTHER

collaborator

National Institute for Medical Research, Tanzania

OTHER_GOV

collaborator

Kilimanjaro Christian Medical Centre, Tanzania

OTHER

lead

London School of Hygiene and Tropical Medicine

OTHER

NCT00158574 - Kilimanjaro IPTi Drug Options Trial | Biotech Hunter | Biotech Hunter